Amphastar Pharmaceuticals Operating Income 2012-2024 | AMPH

Amphastar Pharmaceuticals operating income from 2012 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Amphastar Pharmaceuticals Annual Operating Income
(Millions of US $)
2023 $197
2022 $107
2021 $70
2020 $11
2019 $-0
2018 $-9
2017 $-1
2016 $15
2015 $-7
2014 $-18
2013 $17
2012 $25
2011 $-34
2009 $35
Amphastar Pharmaceuticals Quarterly Operating Income
(Millions of US $)
2024-09-30 $57
2024-06-30 $55
2024-03-31 $48
2023-12-31 $54
2023-09-30 $73
2023-06-30 $37
2023-03-31 $33
2022-12-31 $38
2022-09-30 $23
2022-06-30 $25
2022-03-31 $22
2021-12-31 $24
2021-09-30 $25
2021-06-30 $11
2021-03-31 $10
2020-12-31 $3
2020-09-30 $4
2020-06-30 $-3
2020-03-31 $7
2019-12-31 $-0
2019-09-30 $2
2019-06-30 $1
2019-03-31 $-3
2018-12-31 $2
2018-09-30 $3
2018-06-30 $-3
2018-03-31 $-10
2017-12-31 $-2
2017-09-30 $-3
2017-06-30 $2
2017-03-31 $1
2016-12-31 $-5
2016-09-30 $6
2016-06-30 $10
2016-03-31 $4
2015-12-31 $14
2015-09-30 $-4
2015-06-30 $-10
2015-03-31 $-7
2014-12-31 $-7
2014-09-30 $-8
2014-06-30 $-1
2014-03-31 $-2
2013-12-31 $3
2013-09-30 $0
2013-06-30 $12
2013-03-31 $2
2012-12-31 $52
2012-09-30 $57
2012-06-30 $49
2012-03-31 $46
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.097B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00